Clovis CEO Sees Rosy Future With Rubraca
Executive Summary
Success in the ARIEL3 trial for its ovarian cancer agent and a collaboration with Bristol-Myers Squibb has put Clovis in a healthy position, CEO Patrick Mahaffy tells Scrip.
You may also be interested in...
Tesaro Pumped As PARP Inhibitor Zejula Gets CHMP Nod
While AstraZeneca's rival drug Lynparza is catching up across the Atlantic, this likely approval for Tesaro's ovarian cancer drug will boost the US firm as it aims to make a strong start in the European market.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.